Comparative Dosing of Adjunctive Corticosteroids Therapy for Pneumocystis Pneumonia with ARDS in Non-HIV Immunocompromised Patients
The standard-dose steroid therapy significantly reduced 28-day and 60-day mortality without major complications in the non-HIV immunocompromised population with severe PCP with ARDS. These findings highlight the potential survival benefit of standard-dose corticosteroid regimen in this population.
Authors
- Lujia Guan
- Xiao Tang (ORCID: https://orcid.org/0000-0002-6601-4742)
- Xuyan Li (ORCID: https://orcid.org/0000-0002-0261-8854)
- Chen Wang (ORCID: https://orcid.org/0000-0001-7857-5435)
- Dong Wang (ORCID: https://orcid.org/0000-0001-6928-8725)
- Rui Wang (ORCID: https://orcid.org/0000-0001-5403-1628)
- Bing Sun (ORCID: https://orcid.org/0000-0001-9048-9038)
- Zhaohui Tong (ORCID: https://orcid.org/0000-0002-5341-6857)
- Ying Li (ORCID: https://orcid.org/0000-0002-7595-2212)
Institutions
- Capital Medical University (CN)
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Beijing Chao-Yang Hospital, Capital Medical University (CN)
- China-Japan Friendship Hospital (CN)
- National Clinical Research Center for Digestive Diseases (CN)
Publication Details
- Journal
- Infection and Drug Resistance
- Published
- 2024-12-01
- DOI
- https://doi.org/10.2147/idr.s493298
- Citations
- 2
- Primary Topic
- Pneumocystis jirovecii pneumonia detection and treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.77